Brief: Bolt Biotherapeutics To Present Preclinical Data For Bdc-3042, A Dectin-2-Targeting Agonistic Antibody, At 2023 Aacr Annual Meeting
14/03/2023 22:52
March 14 (Reuters) - Bolt Biotherapeutics Inc BOLT.O :
* BOLT BIOTHERAPEUTICS TO PRESENT PRECLINICAL DATA FOR
BDC-3042, A
DECTIN-2-TARGETING AGONISTIC ANTIBODY, AT 2023 AACR ANNUAL
MEETING
Source text for Eikon: ID:nGNXns2N4
Further company coverage: BOLT.O
((Reuters.Briefs@thomsonreuters.com;))